Status:
COMPLETED
A Study To Assess The Effect Of PF-03893787 On Lung Function Following An Allergen Challenge In Asthmatic Subjects
Lead Sponsor:
Pfizer
Conditions:
Asthma
Eligibility:
All Genders
18-60 years
Phase:
PHASE1
Brief Summary
PF-03893787, a novel anti-inflammatory agent should attenuate the effect of a bronchial allergen challenge on lung function and hence provide proof of mechanism for this agent.
Eligibility Criteria
Inclusion
- Males and females 18-60 years.
- Mild asthma
- Atopic to allergens
Exclusion
- Unstable asthma.
- Smokers or recent ex-smokers
- Recent allergen challenge
Key Trial Info
Start Date :
April 1 2009
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
December 1 2009
Estimated Enrollment :
12 Patients enrolled
Trial Details
Trial ID
NCT00856687
Start Date
April 1 2009
End Date
December 1 2009
Last Update
January 22 2010
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Pfizer Investigational Site
Harrow, Middlesex, United Kingdom, HA1 3UJ